CAS 870281-34-8
:Acalisib
Description:
Acalisib, with the CAS number 870281-34-8, is a selective inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, specifically targeting the delta isoform (PI3Kδ). It is primarily investigated for its potential therapeutic applications in oncology, particularly in the treatment of hematological malignancies and certain solid tumors. Acalisib exhibits a favorable pharmacokinetic profile, allowing for oral administration, and has shown promise in preclinical and clinical studies for its ability to inhibit tumor growth and enhance the efficacy of other cancer therapies. The compound is characterized by its ability to modulate immune responses, making it of interest in both cancer and autoimmune disease research. Its chemical structure includes specific functional groups that contribute to its selectivity and potency. As with many investigational drugs, ongoing studies are essential to fully understand its efficacy, safety profile, and potential side effects in various patient populations.
Formula:C21H16FN7O
Synonyms:- Acalisib (GS-9820)
- UNII-OVW60IDW1D
- 6-Fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-4(3H)-quinazolinone
- Acalisib
- UNII-OVW60IDW1D;ACALISIB (GS-9820);
- 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)ethyl]-
- 6-fluoro-3-phenyl-2-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-3,4-dihydroquinazolin-4-one
- (S)-2-(1-((7H-purin-6-yl)amino)ethyl)-6-fluoro-3-phenylquinazolin-4(3H)-one Acalisib (GS-9820)
- CS-1758
- GS-9820
- Acalisib(GS9820,CAL-120)
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
